

Paul A Monach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9544599/publications.pdf>

Version: 2024-02-01

116
papers

8,975
citations

61984

43
h-index

42399

92
g-index

119
all docs

119
docs citations

119
times ranked

9211
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	27.0	2,275
2	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	27.0	611
3	Antigen microarray profiling of autoantibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2645-2655.	6.7	256
4	The transcriptional landscape of $\hat{1}\pm\hat{1}^2$ T cell differentiation. <i>Nature Immunology</i> , 2013, 14, 619-632.	14.5	256
5	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1329-1334.	0.9	218
6	A unique tumor antigen produced by a single amino acid substitution. <i>Immunity</i> , 1995, 2, 45-59.	14.3	207
7	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.9	196
8	Identification of transcriptional regulators in the mouse immune system. <i>Nature Immunology</i> , 2013, 14, 633-643.	14.5	179
9	Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. <i>Arthritis and Rheumatism</i> , 2010, 62, 9-21.	6.7	175
10	Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2325-2330.	7.1	168
11	The K/BxN Arthritis Model. <i>Current Protocols in Immunology</i> , 2008, 81, Unit 15.22.	3.6	153
12	The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. <i>Nature Communications</i> , 2021, 12, 2856.	12.8	149
13	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
14	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. <i>American Journal of Human Genetics</i> , 2013, 93, 298-305.	6.2	143
15	Association of Granulomatosis With Polyangiitis (Wegener's) With <i>HLA-DPB1*04</i> and <i>SEMA6A</i> Gene Variants: Evidence From Genome-Wide Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2457-2468.	6.7	138
16	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	5.6	132
17	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
18	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130

#	ARTICLE	IF	CITATIONS
19	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1213-1217.	2.0	129
20	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	5.6	116
21	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1342-1350.	0.9	109
22	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
23	The Role of Antibodies in Mouse Models of Rheumatoid Arthritis, and Relevance to Human Disease. <i>Advances in Immunology</i> , 2004, 82, 217-248.	2.2	100
24	Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R76.	3.5	99
25	Neutrophils in a mouse model of autoantibody-mediated arthritis: Critical producers of Fc receptor β_3 , the receptor for C5a, and lymphocyte function-associated antigen 1. <i>Arthritis and Rheumatism</i> , 2010, 62, 753-764.	6.7	95
26	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
27	A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15867-15872.	7.1	88
28	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	2.0	87
29	The K/BxN Mouse Model of Inflammatory Arthritis. <i>Methods in Molecular Medicine</i> , 2007, 136, 269-282.	0.8	85
30	Gene Expression during the Generation and Activation of Mouse Neutrophils: Implication of Novel Functional and Regulatory Pathways. <i>PLoS ONE</i> , 2014, 9, e108553.	2.5	83
31	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
32	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
33	Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	5.6	75
34	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20736-20741.	7.1	74
35	Thromboembolic disease in vasculitis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 41-46.	4.3	73
36	Biomarkers in vasculitis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 24-30.	4.3	63

#	ARTICLE	IF	CITATIONS
37	The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells. <i>Cancer Immunology Research</i> , 2014, 2, 655-667.	3.4	63
38	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3988-3997.	6.7	59
39	ImmGen at 15. <i>Nature Immunology</i> , 2020, 21, 700-703.	14.5	55
40	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	1.9	52
41	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. <i>Journal of Rheumatology</i> , 2012, 39, 303-309.	2.0	51
42	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 251-257.	4.5	50
43	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012, 64, 273-279.	3.4	49
44	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1114-1121.	5.6	49
45	Genetics of vasculitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 157-163.	4.3	45
46	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-associated Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	5.6	45
47	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
48	Point Mutation in Essential Genes with Loss or Mutation of the Second Allele. <i>Journal of Experimental Medicine</i> , 2001, 194, 285-300.	8.5	40
49	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 1905-1912.	2.0	40
50	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.7	40
51	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 674-683.	2.0	39
52	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 1078-1084.	2.0	37
53	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
54	Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. <i>Arthritis and Rheumatology</i> , 2015, 67, 3146-3157.	5.6	36

#	ARTICLE	IF	CITATIONS
55	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	2.5	35
56	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	5.6	34
57	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3463-3471.	6.7	33
58	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33
59	Megakaryocytes compensate for Kit insufficiency in murine arthritis. <i>Journal of Clinical Investigation</i> , 2017, 127, 1714-1724.	8.2	32
60	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
61	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
62	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 535-544.	5.6	25
63	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	5.6	25
64	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
65	The COVID-19 hospitalization metric in the pre- and postvaccination eras as a measure of pandemic severity: A retrospective, nationwide cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1767-1772.	1.8	25
66	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	6.5	24
67	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. <i>Steroids</i> , 2018, 140, 159-166.	1.8	24
68	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	6.5	24
69	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	4.3	24
70	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	5.6	23
71	Primary Angiitis of the Central Nervous System in Adults and Children. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 47-62.	1.9	22
72	Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. <i>Arthritis and Rheumatism</i> , 2007, 56, 2968-2974.	6.7	21

#	ARTICLE	IF	CITATIONS
73	The Pharmacogenomic Association of Fc γ 3 Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 169-175.	5.6	21
74	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
75	Tuberculous osteomyelitis presenting as shoulder pain. <i>Journal of Rheumatology</i> , 2003, 30, 851-6.	2.0	21
76	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , 2018, 57, 639-650.	1.9	20
77	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
78	Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 424-433.	3.4	19
79	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2012, 7, e30197.	2.5	16
80	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	3.1	15
81	Repeating tests: different roles in research studies and clinical medicine. <i>Biomarkers in Medicine</i> , 2012, 6, 691-703.	1.4	14
82	Characterization of relapses in adult idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2006, 25, 476-481.	2.2	13
83	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	4.8	12
84	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	12
85	IgG4-related Disease: 2013 Update. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 214-223.	0.9	11
86	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	3.4	11
87	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2020, 73, 1372-1378.	3.4	11
88	Bringing New Meaning to the Term "Adaptive Trial": Challenges of Conducting Clinical Research During the Coronavirus Disease 2019 Pandemic and Implications for Implementation Science. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa490.	0.9	10
89	Case 6-2017. <i>New England Journal of Medicine</i> , 2017, 376, 775-786.	27.0	9
90	Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100614.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100804.	1.1	9
92	Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study. <i>Vaccine</i> , 2022, 40, 1082-1089.	3.8	9
93	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	5.0	7
94	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 40-44.	0.8	7
95	L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener's). <i>Presse Medicale</i> , 2013, 42, 575-576.	1.9	6
96	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
97	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
98	Clinically isolated aortitis: imaging features and clinical outcomes: comparison with giant cell arteritis and giant cell aortitis. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1433-1443.	1.5	6
99	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	2.1	6
100	ANCA-associated Vasculitis: A Prothrombotic State Even in Remission?. <i>Journal of Rheumatology</i> , 2013, 40, 1935-1937.	2.0	5
101	Reconsidering "minimal risk" to expand the repertoire of trials with waiver of informed consent for research. <i>BMJ Open</i> , 2021, 11, e048534.	1.9	5
102	Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2017, , 1541-1558.e4.		4
103	Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches. <i>Lancet Rheumatology</i> , The, 2019, 1, e247-e256.	3.9	4
104	Identification of Acute Giant Cell Arteritis in Real-World Data Using Administrative Claims-Based Algorithms. <i>ACR Open Rheumatology</i> , 2021, 3, 72-78.	2.1	4
105	Coronavirus disease 2019 (COVID-19) hospitalization metrics that do not account for disease severity underestimate protection provided by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination and boosting: A retrospective cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 149-151.	1.8	4
106	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.8	3
107	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.8	3
108	Global versus organ-specific outcome measures in systemic lupus erythematosus: Comment on the articles by Furie et al, Nikpour et al, Wallace et al, Burgos et al, and Ramos-Casals et al. <i>Arthritis Care and Research</i> , 2010, 62, 580-581.	3.4	2

#	ARTICLE	IF	CITATIONS
109	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	1.9	2
110	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
111	Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 385, 764-765.	27.0	1
112	The rheumatoid joint. , 2015, , 768-784.		1
113	Does knee malalignment predispose to osteoarthritis? Comment on the articles by Brouwer et al and Hunter et al and the editorial by Sharma. <i>Arthritis and Rheumatism</i> , 2007, 56, 3872-3872.	6.7	0
114	Assessing Performance of Internal Medicine Residents. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1276.	7.4	0
115	SAT0012â€¦DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
116	Purification of tumor antigens recognized by CD4+ T lymphocytes. , 1996, , 1319-1326.		0